Skip to main content
. 2020 Mar 3;9(6):661–673. doi: 10.1002/sctm.19-0220

Figure 2.

Figure 2

TPO enhances engraftment of HSPCs to the BM. A, Schematic representation of the homed CD45.1+ BM cell engraftment assays from the competitive and noncompetitive transplantation experiments. Lethally irradiated CD45.2+ mice (1° recipients) received CD45.1+ BM MNCs and single doses of TPO or PBS treatment (mean ± SD, n = 8 for the control group and n = 10 for the TPO treatment group). B, Flow cytometric analyses of the donor CD45.1+ cell percentages in the PB at 4, 8, and 12 weeks after 2° transplantation (mean ± SD, n = 8 for the control group and n = 10 for the TPO treatment group). C, The percentages of donor CD45.1+ cells in the 2° recipient BMs at 20 weeks after transplantation. D,E, Representative dot plots and percentages of donor LSK cells (CD45.1+CD45.2−LSK) in the 2° recipient BMs at 20 weeks after 2° transplantation. F, The donor CD45.1+ blood lineage cell percentages in the 3° recipients at 16 weeks after transplantation (mean ± SD, n = 5 for the control group and n = 6 for the TPO treatment group). BM, bone marrow; HSPC, hematopoietic stem and progenitor cell; MNC, mononuclear cell; PBS, phosphate‐buffered saline; TPO, thrombopoietin